SPX and metabolic syndrome: Neuropeptide Q serum concentration in metabolic syndrome subjects was significantly lower than in the controls (0.47 (0.34 ; 0.54) vs. 0.52 (0.43 ; 0.60) ng/mL; p = 0.015).